Driven by Innovation
ONE-STOP CDMO
FOR mRNA, CELL AND GENE THERAPY
Driven by Innovation
ONE-STOP CDMO
FOR mRNA, CELL AND GENE THERAPY
ABOUT US +
Innoforce is a premier CDMO focusing on Advanced Therapy Medicinal Products (“ATMP”). We have developed comprehensive technology platforms to enable end-to-end manufacture of high-quality plasmid DNA, RNA, LNP, viral vectors, and cell therapeutics. Our state-of-the-art facility is designed to meet the cGMP standards of the FDA, EMA, and NMPA. We have also implemented rigorous policies and procedures to safeguard our clients’ IP. Innoforce is led by an industry-seasoned management team with extensive experience leading multiple innovative products from development to commercialization in the US, EU, and China. Our goal is to accelerate the development and commercialization of innovative products globally. With our expertise in process development and manufacturing, Innoforce can be a trusted partner from R&D through commercialization.
LEARN MORE
BUSINESS MODALITIES +
Plasmid DNA
RNA IVT
LNP Encapsulation
Viral Vectors
Plasmid DNA
Plasmid DNA is a starting material for advanced therapy medicinal products (ATMP), including RNA therapy, viral vector-based cell therapy and gene therapy. Innoforce has a broad-spectrum of proprietary technologies in development and manufacturing of plasmid DNA. We offer different grades and services to support your programs from pre-clinical phase through clinical and commercial phases.
RNA IVT
The rapid advances in mRNA technology enable the introduction of any functional proteins into the human body, bringing great hope to combat a wide range of incurable diseases. Innoforce integrates innovation and accumulated experience to deliver best-in-class mRNA products and streamline the development of your mRNA therapeutics.
LNP Encapsulation
The instability of the mRNA structure makes it easy to degrade in vivo. Lipid nanoparticles (LNP) are one of the most commonly used delivery systems that allow mRNA to release safely and effectively in target organs. With years of dedication to developing LNP delivery systems, Innoforce possesses a series of proprietary technologies and robust manufacturing processes.
Viral Vectors
As a technical-driven CDMO, we are committed to delivering innovative technologies and scale-up knowledge to bring reliable and high-quality products to clients. Our expertise in viral vector manufacturing addresses challenges in purification, scaling up and control, and we share in-depth knowledge across different viral vectors, including lentiviral vectors, AAV and retrovirus.
ADVANTAGES +
Experienced Technical Team
We are led by an industry seasoned management team who spent years in leading biopharma and biotech companies driving multiple successful innovative biologics from development through commercialization. We want to help your project achieve the same success with our expertise and experience.
End-to-end Service
Our state-of-the-art process development center and GMP facility support end-to-end CDMO service from process development through commercial GMP manufacturing, including primary ATMP modalities (RNA, LNP, viral vectors and cell therapy).
Events
2024-01-11 2024 Advanced Therapies Week View all news
2024-01-08 2024 JP Morgan Week | The Global CDMO Summit View all news
2023-12-19 Innoforce’s Partner RNAimmune Granted IND Clearance for RSV mRNA Vaccine from FDA View all news
2023-11-14 BioProcess International Fall Digital Week View all news
2023-09-23 CMC Considerations and Strategies for Nucleic Acid Medicines View all news
2023-09-19 Cell & Gene Therapy Manufacturing & Commercialization US (BioProcess International 2023) View all news
1500 Fannie Dorsey Road Sykesville, MD 21784 USA +1 (224) 430-0311 cdmo@innoforcepharma.com
No. 376 Fengtu Street, Xiaoshan District, Hangzhou, China +86 571 8281 6679 cdmo@innoforcepharma.com
Copyright © 2023 Terms and Conditlons Privacy Policy 浙ICP备19036307号-2 POWERED BY:YUSHANGWEB

Topping